摘要
目的探讨养正消积胶囊辅助应用于非小细胞肺癌化疗的临床疗效。方法选择接受化疗的初治非小细胞肺癌患者78例,根据患者意愿分为观察组和对照组各39例。2组均给予常规化疗,以21 d为1个化疗周期,均完成4个周期化疗。观察组同时在常规化疗基础上给予养正消积胶囊口服6周以上。观察比较2组化疗结束后临床疗效、生活质量(KPS评分)、体质量及化疗毒副反应(消化道反应及血液毒性反应)。结果 2组近期疗效比较差异无统计学意义(P>0.05);观察组KPS评分升高和体质量增加比例均明显高于对照组(P均<0.05),而重度消化道反应和血液毒性反应发生率均明显低于对照组(P均<0.05)。结论养正消积胶囊辅助用于非小细胞肺癌的一线化疗方案未能提高化疗疗效,但可明显改善患者化疗后体质量下降,减轻消化道反应和血液毒性反应,提高患者生活质量。
Objective It is to explore the clinical efficacy of Yangzheng Xiaoji Capsule in the treatment of non-small cell lung cancer chemotherapy. Methods 78 patients with newly diagnosed non-small cell lung cancer who received chemotherapy were divided into observation group and control group according to the patient's wishes. Both groups were given conventional chemotherapy, 21 days as a chemotherapy cycle, and 4 cycles of chemotherapy were completed. The observation group was treated with Yangzheng Xiaoji Capsule for more than 6 weeks on the basis of conventional chemotherapy. The clinical efficacy, quality of life(KPS score), body mass and chemotherapy side effects(digestive tract reaction and hematological toxicity) of the two groups after chemotherapy were observed and compared. Results There was no significant difference in the short-term efficacy between the two groups(P>0.05). The proportion of increase of KPS score and body mass in the observation group were significantly higher than those in the control group(P<0.05), but the incidence of severe gastrointestinal reaction and hematological toxicity reaction was significantly lower than that of the control group(P<0.05). Conclusion Yangzheng Xiaoji Capsule has not improved the efficacy of chemotherapy in the first-line chemotherapy for non-small cell lung cancer, but it can significantly improve the body weight loss after chemotherapy, reduce the digestive tract reaction and blood toxicity, and improve the quality of life of patients.
引文
[1] 陶李蕙苹,沈政洁,李柳,等. 中医药治疗恶性肿瘤系统综述/Meta分析的现状评价[J]. 中华中医药学刊,2017,25(12):3126-3130
[2] 皋文君,刘砚燕,袁长荣. 国际肿瘤化疗药物不良反应评价系统一通用不良反应术语标准4.0版[J]. 肿瘤,2012,32(2):142-144
[3] 李静,任小沧. 香菇多糖联合化疗治疗肺癌的疗效及免疫功能影响[J]. 中华肿瘤防治杂志,2016(S1):98-99
[4] Seo SH,Kim SE,Kang YK,et al. Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients[J]. BMC Cancer,2016,16(1):900
[5] 林征,林琳,张红杰,等. 功能性便秘患者社会、心理、行为状况调查及生物反馈治疗效果随访[J]. 中国临床康复,2005,9(28):67-69
[6] 田劭丹,董青,祁烁,等. 化疗后白细胞减少症中医药防治与评估专家共识[J]. 现代中医临床,2018,25(3):1-6
[7] Zadák Z,Hyspler R,Dytrych V. Nutritional support and tumor diseases[J]. Vnitr Lek,2002,48(7):595-597
[8] Mardas M,Madry R. Link between diet and chemotherapy related gastrointestinal side effects[J]. Stelmach-Mardas M.Contemp Oncol(Pozn),2017,21(2):162-167
[9] 陈晓慧,鱼芳,陈志盛,等. 化疗引起的消化道黏膜炎与肠道菌群相关性的研究进展[J]. 中国微生态学杂志,2016,28(8):991-992
[10] 贾永宁,季科,叶林,等. 养正消积抗肿瘤作用的机制[J]. 肿瘤药学,2013,3(5):322-325
[11] Ye L,Ji K,Frewer N,et al. Impact of Yangzheng Xiaoji on the adhesion and migration of human cancer cells: the role of the AKT signalling pathway[J]. Anticancer Res,2012,32(7):2537-2543
[12] Thamilselvan V,Craig DH,Basson MD. FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway[J]. FASEB J,2007,21(8):1730-1741
[13] Li L,Xia Y,Wang Z,et al. Suppression of the PI3K-Akt pathway is involved in the decreased adhesion and migration of bone marrow-derived mesenchymal stem cells from non-obese diabetic mice[J]. Cell Biol Int,2011,35(9):961-966
[14] Zhang F,Zhang T,Jiang T,et al. Wortmannin potentiates roscovitine-induced growth inhibition in human solid tumor cells by repressing PI3K/Akt pathway[J]. Cancer Lett,2009,286(2):232-239
[15] Chung BH,Cho YL,Kim JD,et al. Promotion of direct angiogenesis in vitro and in vivo by Puerariae flos extract via activation of MEK/ERK-,PI3K/Akt/eNOS-,and Src/FAK-dependent pathways[J]. Phytother Res,2010,24(6):934-940
[16] 邢力刚,赵汉玺,李贵新,等. 晚期肺癌养正消积胶囊联合化疗临床对照研究[J]. 中华肿瘤防治杂志,2014,21(5):384-386
[17] 王军. 养正消积胶囊辅助治疗对原发性肝癌患者肿瘤标志物及生活质量的影响[J]. 中国老年学杂志,2015,35(10):5827-5829
